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Abstract
Dynamic treatment regimes (DTRs) are used to operationalize treatment decision-making at different
stages by clinicians. The decision rules are based on the time-varying patient characteristics. DTRs
can provide more effective decisions compared with once-and-for-all decisions. Here we compare two
approaches to identify a set of DTRs that includes the optimal DTR. The methods are: the ACI
(Adaptive Confidence Intervals) method by Laber et al. with our modifications and the MCB (Multiple
Comparisons with the Best) method by Ertefaie et al. We simulate data from four different scenarios to
compare the MCB method and a modified version of the ACI method. By comparing the probabilities
that the best DTR is included into the constructed set, and the average set size of each method in four
different scenarios, we find that both methods include the true optimal DTR with a specified probability.
The MCB method generally has a smaller average set size, indicating that it has more power in excluding
inferior DTRs. Thus, we conclude that MCB method performs better in general.
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1 Introduction
1.1 DTR and SMART
Individualized treatments enhance health care providers’ management to different patients.
Decisions at different stages are made based on patients’ responses to their previous treatments.
Since adaptive decisions at different stages are based on accumulative observations, they
increase the effectiveness and the efficiency of the treatments compared with once-and-for-all
decisions for patients. Dynamic Treatment Regimes (DTRs), also called adaptive interventions
[1] or adaptive treatment strategies [5] [6] [10] [13] [14], are sequences of decision rules,
which are based on patients’ characteristics over time and provide treatment decisions.
The rules take information before the current decision-making as inputs and sugggest the
treatment decision at this stage. Thus, the rules make it possible for clinicians to consider
the combination of factors at different stages. However, the selection of the optimal DTR
among multiple ones requires researchers to develop methods and design experiments such
that clinicians can provide the best outcome for patients.
In recent years a design known as sequential multiple assignment randomized trials
(SMART) [10], has been applied to find the optimal DTR that has the maximum expected
outcome among all possible DTRs. The SMART design starts with a randomization of
individuals to available treatment options, then based on the intermediate outcome at each
stage, individuals are re-randomized to receive the next stage’s treatment. This method
guarantees that the assignments of treatment among patients are not correlated and that
the outcome is conditional on the patients’ response overtime until the current stage [16].
1
2SMART trials have three advantages over traditional methods: better validation for finding
if one treatment is enhanced by prior treatments, better validation for detecting if an initial
treatment is useful for upcoming decisions, and consideration of nonresponse cases at each
stage to make patients a good representative of the population [7].
Figure 1: A Simple SMART Design
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A simple SMART design as a
two-stage treatment is shown as
follows: we use a time-ordered
trajectory
(X1, A1, X2, A2, Y )
to record the process. X1 is
called baseline information, which
contains the initial condition of
a patient before the first stage
treatment. A1 is the treatment
on the first stage, and is coded
as binary values {-1,1}. X2 is
the response to the first stage
treatment before the second stage
treatment, and is coded as binary
values {-1,1} with 1 indicating
“Yes” and -1 indicating “No”. A2
is the second stage treatment with
binary values {-1,1}. Y is the final
stage outcome of the regime and is
coded such that a higher value is preferred.
1.2 Literature Reivew
So far, different methods have been proposed to help estimate the optimal DTR(s) using
the SMART design. Murphy [9] proposed an approach called A-learning to construct and
optimize regret functions using the dynamic programming method. The optimization of the
regret function at each stage provides the optimal treatment regime. This method was later
applied into various studies. Huang et al. [3] used the A-learning method and accelerated
failure time models to identify the optimal treatment regime for recurrent diseases. Another
method called Q-learning was applied by Murphy [11] and Zhao et al. [15] to obtain the
optimal DTR using the dynamic programming technique. Parametric, semi-parametric, or
nonparametric Q-functions can be applied to Q-learning and related methods. Backward
induction helps find the optimal treatment regime. The Q-learning method is efficient for
a single-stage setting if the simple linear regression model is specified, and it is widely
used when there are a limited number of treatments at each stage [8]. In addition, Zhao et
al. [16] proposed Backward Outcome Weighted learning (BOWL) and Simultaneous Outcome
Weighted Learning (SOWL) to find the optimal treatment regime. By assuming optimal
regimes are obtained in the following stages, Zhao et al. maximized the optimal decision
rule at the current stage. These methods perform well in specific settings. All the techniques
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goal in some clinical trials. As will be discussed in the following section, the Multiple
Comparisons with the Best (MCB) method developed by Ertefaie et al. [2] identifies a set
of DTRs that excludes DTRs with lower expected outcomes among multiple ones, and this
provides more flexibility for clinicians to make decisions for their patients. All the methods
mentioned above might have been tested in some situations, but they might not work well
in all situations. Thus, the comparison between different methods to select a better one for
each situation requires further exploration.
1.3 Goal
In this paper, we focus on two different methods introduced by two groups of researchers.
There are the ACI (Adaptive Confidence Intervals) method proposed by Laber et al. [4] and
the MCB method developed by Ertefaie et al. [2]. These two groups applied different methods
that return either the optimal DTR or a set of DTRs. In this study, we used a modified
version of the ACI method to obtain a set of DTRs, and the details of the modification
can be found in section 2.2. The goals of this paper are: 1) to simulate data from different
scenarios to test if the two methods include the optimal DTR(s) in their sets, and 2) to
assess how well the two methods perform in excluding non-optimal DTRs.
The rest of this paper is organized as follows: Section 2 discusses the two methods
developed by Laber et al. [4] and Ertefaie et al. [2], and the modification of the ACI method;
Section 3 talks about simulation design and simulation results; Section 4 is the illustrative
data analysis; Section 5 is discussion and conclusion.
2 ACI and MCB Methods
2.1 ACI Method by Laber et al. [4]
To find the optimal DTR, Laber el al. introduced a method of constructing adaptive
confidence intervals (ACIs) for the Q-Learning algorithm’s parameters in a regression model
in 2011. After obtaining smooth, data-dependent upper and lower bounds for each parameter,
confidence intervals of those parameters are constructed using the bootstrapping technique.
Non-regularity in the Q-Learning method can occur during the maximization of the estimation
process since it is a non-smooth and non-linear operation. Based on the setup in our study,
non-regularity occurs when the effects of the two treatments are close at the second stage.
This can further lead to a biased estimation of the effect of the first stage treatment. Laber
et al. are targeted with the problem of the non-regularity of the Q-Learning method. The
construction of high quality confidence intervals can efficiently reduce the bias of parameters
that lead to huge mean square errors. In this way, although ACIs are still conservative for
non-regular generative models, they are asymptotically valid.
Considering a two-stage treatment, the common Q-Learning algorithm functions are
described below:
Q2(h2, a2) , E(Y2|H2 = h2, A2 = a2)
4Q1(h1, a1) , E(Y1 + max
a2∈{1,−1}
Q2(H2, a2)|H1 = h1, A1 = a1);
In the above equations, Qi(hi, ai), i = 1, 2 are called Q-functions. Hi is the joint
expectation over the patient’s history, and Hi includes information from the beginning up
to the decision for the ith stage treatment Ai. Correspondingly, in our project, H1 = X1,
and H2 contains X2.
In order to obtain the means in the functions, Laber et al. used a linear model. The
linear model and estimator of each stage is as follows:
Qi(hi, ai; βi) = β
T
i,0hi,0 + β
T
i,1hi,11ai=1 (1)
βˆi , argmin
βi
Pn(Yi −Qi(Hi, Ai; βi))2 (2)
where i = {1, 2}.
Plug βˆ2 into the predicted future reward, which is defined as:
Y˜1 , Y1 + max
a2∈{1,−1}
Q2(H2, A2; βˆ2) = Y1 +H
T
2,0βˆ2,0 + [H
T
2,1βˆ2,1]+
where [HT2,1βˆ2,1]+ represents the positive part of H
T
2,1βˆ2,1.
By regressing Y˜1 on H1 and A1 using (3), we can obtain βˆ1.
The optimal DTR aˆ = (aˆ1, aˆ2) is:
aˆt(hi) , arg max
ai∈{1,−1}
Qt(hi, ai; βˆi) (3)
Laber et al. introduced a method using preliminary hypothesis testing (pretesting) and
bootstrapping for individuals in the data to obtain confidence intervals for linear combinations
of βi. In this way, the obtained ACIs asymptotically cover when there is a treatment effect
for all patients.
2.2 The Modification of the ACI Method
In order to construct a set of DTRs where the optimal DTR is included, we modified the
ACI method. The modifications are as follows:
First of all, three types of hypothesis tests are conducted: the comparison of the two
first stage treatments using the confidence interval obtained from the ACI method, the
comparison of the two second stage treatments for the responders of the first stage using
regular confidence intervals, and the comparison of the two second stage treatments for
non-responders of the first stage using regular confidence intervals. For each type of the
hypothesis tests, the significance level is set as α/3, where α = 0.05 in our study. For each
type of the hypothesis tests, only one treatment is ruled out if it is significantly worse than
the other, and neither is excluded when there is no significant difference between the two
treatments. Then, a DTR is included in the recommended set if and only if none of its first
stage treatment option, its second stage treatment option for responders, or its second stage
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the DTRs based on the above rules.
2.3 MCB Method by Ertefaie et al. [2]
Ertefaie et al. concentrated on methods of multiple comparison of group means, since this
method is able to control the Type one error efficiently and hence increases the statistical
power. They proposed a method to identify a set of means using Multiple Comparisons with
the Best (MCB) technique, which compares the mean of each DTR with the best mean and
recognizes DTRs that are significantly below the best, and then returns a set of DTRs that
includes the optimal DTR.
Based on the analysis of the Extending Treatment Effectiveness of Naltrexone (EXTEND)
study [12], the researchers first estimated the mean outcome under each DTR in the EXTEND
study. The Marginal structural model (MSM) was applied in the estimation and two
methods were used for the model: inverse probability weighting (IPW) and augmented
inverse probability weighting (AIPW). The estimating equations are as follows:
1. Inverse probability weighting (IPW):
Inverse probability weighting (IPW) takes in a v-treatment trajectory τ and a function
of β named θk. The estimation of the parameters in the model is based on the following
equation:
Pn
K∑
k=1
m˙(τ, β)w2(V, A¯2, k)(Y −m(τ ; β)) = 0,
where m˙(τ, β) = ∂m(τ, β)/∂β and
w2(V, A¯2, k) =
IDTRk,1 (a1)IDTRvk,2
(a2)
p(A1=a1)p(A2=a2|A1=a1,V=v) for V = v and A¯2 = a¯2
The treatment options for stage 2 based on V for DTR k is denoted as DTRvk,2(a2)
2. Inverse probability weighting (AIPW):
The estimation equation of AIPW is as follows:
Pn
K∑
k=1
m˙(τ, β)[w2(V, A¯2, k)(Y −m(τ ; β))− (w2(V, A¯2, k)− w1(A¯1, k))(ϕk2(X¯2)−m(τ ; β))
− (w1(A1, k)− 1)(ϕk1(X¯1)−m(τ ; β)) = 0,
where ϕk2(X¯2) = E[Y |A¯2 ∈ DTRvk,2(X¯2)] , ϕk1(X¯1) = E[ϕk2(X¯2)|A¯1 ∈ DTRvk,1(X¯1)]
and
w1(a1, k) =
IDTRk,1 (a1)
p(A1=a1)
, for A1 = a1
After obtaining the estimated best mean of each DTR, Ertefaie et al. generalized the
MCB method to find DTRs that were not significantly different from the set of DTRs that
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as B) such that [K] := arg maxk=1,··· ,K θk belongs to the set with a probability no smaller
than a pre-specified level, say, 1 − α. θk represents the mean outcome of each DTR with k
= 1 to K, and θˆk is obtained by applying MSM and IPW to represent the estimation of each
θk. This method ensures that the best DTR is contained in the set with the pre-specified
probability, and provides more options for healthcare providers to select among DTRs that
are within the acceptance range.
3 Simulation
3.1 Simulation Setup
Simulations in this article are constructed based on a two-stage SMART design, and the
generative model for final outcome Y is set as follows:
Y = γ1 + γ2X1 + γ3A1 + γ4X1A1 + γ5A2 + γ6X2A2 + γ7A1A2 + ,  ∼ N(0, 1)
where Y is the final stage outcome; Ai = {1, -1} is the ith stage treatment decision for i =
1, 2; Xi = {1, -1} is the ith stage outcome for i = 1, 2.
This setup allows different scenarios to be constructed by using different sets of γ vector
(γ1, γ2, γ3, γ4, γ5, γ6, γ7) and δ vector (δ1, δ2) that determines X2|X1, A1 as X2|X1, A1 ∼
Bernoulli(expit(δ1X1 + δ2A1)), expit(x) = e
x/(1 + ex) . For example, if the γ vector is
(0, 0, 0.1, 0, 0.1, 0, 0) and the δ vector is (0, 0), the model becomes Y = 0.1A1 + 0.1A2 + . In
order to select the best DTR and obtain the maximized expected final outcome Y, both A1
and A2 have to be set as 1. Thus the optimal DTR is obtained: we choose A1 = 1 at the
first stage and always choose A2 = 1 at the second stage regardless of X1.
The ways to determine whether the modified ACI or the MCB is a better method in
different scenarios are: 1) by comparing the probabilities that the best DTRs are included
into the constructed set, and 2) by comparing the average set size from each method, which
is the sum of probabilities of including each of the DTRs for each method. The former tests
if the two methods are able to include the optimal DTR with the pre-specified probability,
and the latter can be used as an additional gauge to test how good the two methods are
in excluding non-optimal DTRs. The method that both reaches the desired probability of
containing the optimal DTR and has a relatively smaller average set size is the better method
in this setting.
Four different scenarios are constructed in this paper based on the above rules, and the
results are presented in the following subsection. Three scenarios with the occurrences of
non-regularity are constructed by setting the two treatments at the second stage to be equally
best in all or some DTRs. A scenario with no non-regularity is also constructed when there
are two optimal DTRs. In the following four scenarios, the δ vector is set to be (0,0),
indicating that the probability of a patient responding to a treatment is 0.5.
73.2 Scenarios and Results
3.2.1 Scenario One
In scenario one, all eight DTRs are equally optimal. In this scenario, different sample sizes
in each setting are used. In addition, slightly altered γ3 values are assigned as well, and
as γ3 changes from 0 to positive values, the optimal DTRs changes to when the first stage
treatment selection is A1 = 1. In Table 1, We find that the MCB method performs better
than the modified ACI method.
Table 1: Results of Scenario One
Number
of
iteration,
Sample
size
γ vector setting
Best
DTR
index
Best DTR
Probabilities
for the
modified ACI
Best DTR
Probabilities
for the MCB
AVG
set size
for the
modified
ACI
AVG
set size
for the
MCB
10000
150
( 0,0,0,0,0,0,0) 1-8
0.96 0.97
0.96 0.96
0.96 0.96
0.96 0.96
0.96 0.94
0.94 0.94
0.94 0.98
0.97 0.94
7.70 7.52
10000
300
( 0,0,0,0,0,0,0) 1-8
0.96 0.96
0.96 0.97
0.97 0.96
0.96 0.96
0.94 0.95
0.95 0.95
0.94 0.94
0.94 0.95
7.70 7.56
10000
600
( 0,0,0,0,0,0,0) 1-8
0.96 0.96
0.96 0.97
0.97 0.96
0.96 0.96
0.94 0.95
0.95 0.95
0.95 0.95
0.95 0.95
7.71 7.57
2000
150
( 0,0,0.01,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.94 0.95
0.95 0.94
7.70 7.47
2000
150
( 0,0,0.05,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.95 0.96
0.96 0.96
7.69 7.37
2000
150
( 0,0,0.1,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.96 0.97
0.97 0.97
7.65 7.03
2000
150
( 0,0,0.2,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.97 0.97
0.97 0.97
7.33 5.76
2000
150
( 0,0,0.3,0,0,0,0) 1-4
0.97 0.97
0.96 0.96
0.97 0.97
0.97 0.97
6.47 4.52
3.2.2 Scenario Two
In scenario two, the final outcomes are different by the second stage decision A2 if the first
stage decision A1 is 1, but are the same if the first stage decision A1 is -1. In Table 2, we
find that both methods have similar performance, with a slightly better result from MCB.
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Iteration,
Sample
size
γ vector setting
Best
DTR
index
Best DTR
Probabilities
for the
modified
ACI
Best DTR
Probabilities
for the
MCB
AVG
set size
for the
modified
ACI
AVG
set size
for the
MCB
10000
150
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.98
0.96
0.96
0.96
0.96
0.97
0.96
0.96
0.96
0.96
4.83 4.82
10000
300
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.98
0.96
0.96
0.96
0.96
0.97
0.96
0.97
0.97
0.97
4.83 4.83
10000
600
( 0,0,-0.5,0,0.5,0,0.5)
1
5
6
7
8
0.99
0.97
0.96
0.96
0.96
0.97
0.97
0.97
0.97
0.97
4.84 4.83
2000
150
( 0,0,-0.49,0,0.51,0,0.51) 1 0.99 0.98 4.83 4.80
2000
150
( 0,0,-0.5,0,0.5,0,0.5)
1
4
0.99
0.97
0.97
0.97
4.82 4.81
3.2.3 Scenario Three
In scenario three, responders to the first stage have the same final outcomes to A2, but
non-responders have different expected final outcomes to A2. In Table 3, we find that the
MCB method performs better than the modified ACI method.
Table 3: Results of Scenario Three
Iteration,
Sample
size
γ vector setting
Best
DTR
index
Best DTR
Probabilities
for the
modified
ACI
Best DTR
Probabilities
for the MCB
AVG
set size
for the
modified
ACI
AVG
set size
for the
MCB
2000
150
( 0,0,0,0,0.5,-0.5,0)
1
3
5
7
0.98
0.97
0.97
0.97
0.97
0.97
0.96
0.96
3.89 3.88
2000
150
( 0,0,0.01,0,0.5,-0.5,0)
1
3
0.98
0.97
0.98
0.97
3.89 3.88
92000
150
( 0,0,0.05,0,0.5,-0.5,0)
1
3
0.99
0.98
0.98
0.98
3.88 3.85
2000
150
( 0,0,0.1,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.98
3.85 3.77
2000
150
( 0,0,0.2,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.99
3.60 3.35
2000
150
( 0,0,0.3,0,0.5,-0.5,0)
1
3
0.99
0.98
0.99
0.99
3.16 2.79
3.2.4 Scenario Four
In scenario four, we manipulated the γ vector such that only one or two optimal DTRs will
be obtained in this case, and there is no non-regularity. In Table 4, we find that the modified
ACI method performs better than the MCB method. Because there is no non-regularity in
this scenario, the modified ACI method will not be conservative compared to its performance
in the first three scenarios. Also, since there are only two optimal DTRs in this scenario, and
the MCB method still uses the critical value for comparing all eight DTRs when it chooses
a set in this case, the result of the MCB method will be conservative.
Table 4: Results of Scenario Four
Iteration,
Sample
size
γ vector setting
Best
DTR
index
Best DTR
Probabilities
for the
modified
ACI
Best DTR
Probabilities
for the MCB
AVG
set size
for the
modified
ACI
AVG
set size
for the
MCB
2000
150
( 0,0,-1,0,-1,0,-0.5)
4
8
0.98
0.98
0.99
0.99
1.96 1.98
2000
150
( 0,0,-0.99,0,-1,0,-0.5) 4 0.98 0.99 1.96 1.98
2000
150
( 0,0,-0.45,0,-1,0,-0.5) 4 0.99 0.99 1.95 1.98
2000
150
( 0,0,-0.4,0,-1,0,-0.5) 4 1.00 1.00 1.93 1.96
2000
150
( 0,0,-0.51,0,-1,0,-0.5) 8 0.98 0.99 1.96 1.98
2000
150
( 0,0,-0.55,0,-1,0,-0.5) 8 0.99 1.00 1.95 1.98
2000
150
( 0,0,-0.6,0,-1,0,-0.5) 8 1.00 1.00 1.92 1.96
10
4 Illustrative Data Analysis
In this project, we use the Extending Treatment Effectiveness of Naltrexone (EXTEND)
study [12] to illustrate the comparison of the two methods. The EXTEND study is a
24-week, two-stage study. Naltrexone (NTX) is used in the experiment as a treatment to
prevent the relapse of alcoholism. The initial sample size was 302 and 250 patients in total
were re-randomized at the second stage. The design is shown below, and there are in total
eight DTRs in this experiment. In the EXTEND study, the final outcomes are measured
as the percentage of heavy drinking days and the percentage of the drinking days over the
last two months of the EXTEND study, and lower percentages represent better outcomes.
Detailed information about the EXTEND study can be found in Lei et al. in 2012 [7].
R
Lenient non-responder criterion (N=127) A1 = 1
Stingent non-responder criterion (N=123) A1 = −1
Response?
Response?
R
No
R
No
R
Yes
R
Yes
NTX (N=50) A2 = −1
NTX+TDM (N=53) A2 = 1
NTX (N=41) A2 = −1
NTX+TDM (N=39) A2 = 1
NTX+CBI (N=14) A2 = 1
CBI (N=10) A2 = −1
NTX+CBI (N=20) A2 = 1
CBI (N=23) A2 = −1
We use the ten imputed datasets
from the EXTEND data. The
missing data were inputed using
standard imputation methods (For
details please email wutiansh@umich.edu).
For the modified ACI method, the
output set of DTRs in each dataset
includes all eight DTRs. The
MCB method, however, excludes
some of the DTRs in some
cases. Specifically, among the
ten datasets, four of them include
eight DTRs, three of them include
seven DTRs and the remaining
three include six DTRs. As a
result, the MCB method in this
study can exclude some of the relatively worse DTRs among the eight DTRs, while the
modified ACI method fails to exclude DTRs in any of the datasets. In this study, the
estimated effects of the eight DTRs are close, indicating that it is likely to be the setting of
Scenario One in our simulation study, where MCB has better power.
5 Discussion and Conclusion
Based on the simulation results from the four different scenarios, we find that the MCB
method performs better than the modified ACI method in general. Among the four simulation
scenarios, the MCB method has a better performance three out of four times compared to the
modified ACI method. The modified ACI method performs better in the scenario where there
is no non-regularity, but the MCB method has higher performance in the other scenarios.
One possible explanation for the result is that the modified ACI method can possibly be
improved by choosing better significance levels for different hypothesis tests. In our study,
the significance levels for all three hypothesis tests are set to be α/3 , where α = 0.05. We
will further investigate the possibility of combining the two methods so that the new method
can improve the performance.
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